ExodusPoint Capital Management LP Invests $356,000 in Amedisys, Inc. (NASDAQ:AMED)

ExodusPoint Capital Management LP purchased a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,923 shares of the health services provider's stock, valued at approximately $356,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Amedisys by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock worth $291,992,000 after buying an additional 10,817 shares during the last quarter. Norges Bank purchased a new stake in shares of Amedisys during the fourth quarter valued at $83,061,000. Alpine Associates Management Inc. lifted its stake in Amedisys by 3.2% during the 4th quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider's stock valued at $80,632,000 after acquiring an additional 27,403 shares during the period. Wealthfront Advisers LLC purchased a new stake in shares of Amedisys during the 4th quarter valued at about $72,970,000. Finally, Alliancebernstein L.P. raised its holdings in shares of Amedisys by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 677,787 shares of the health services provider's stock valued at $61,536,000 after purchasing an additional 13,587 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on AMED shares. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada restated an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research report on Wednesday. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $100.75.

Amedisys Trading Down 0.2 %

Shares of NASDAQ AMED traded down $0.15 during trading on Friday, reaching $91.76. The stock had a trading volume of 133,860 shares, compared to its average volume of 399,630. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market cap of $3.01 billion, a P/E ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89. The business's 50-day moving average price is $92.16 and its 200-day moving average price is $91.94. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. On average, equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.